Evidence map›Paper›PMID 37769001›Full record

ArticlePloS one2023

Evaluation of a human mucosal tissue explant model for SARS-CoV-2 replication.

Bhavna Gowan Gordhan, Carolina Herrera, Azure-Dee Pillay, Thabiso Seiphetlo, Christopher Shawn Ealand, Edith Machowski, Natasha Singh, Ntombexolo Seatholo, Kennedy Otwombe, Limakatso Lebina and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 5 countries.

Bhavna Gowan GordhanFaculty of Health Sciences, Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical TB Research, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa.
Carolina HerreraDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Azure-Dee PillayFaculty of Health Sciences, Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
Thabiso SeiphetloFaculty of Health Sciences, Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
Christopher Shawn EalandFaculty of Health Sciences, Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical TB Research, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa.
Edith MachowskiFaculty of Health Sciences, Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical TB Research, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa.
Natasha SinghFaculty of Health Sciences, Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
Ntombexolo SeatholoFaculty of Health Sciences, Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
Kennedy OtwombeFaculty of Health Sciences, Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
Limakatso LebinaFaculty of Health Sciences, Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
Rebecca FriseDepartment of Infectious Disease, Imperial College London, London, United Kingdom.
Gabriella ScarlattiViral Evolution and Transmission Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
Francesca ChiodiDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden.
Neil MartinsonFaculty of Health Sciences, Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South Africa.
Julie FoxGuys and St. Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.
Bavesh Davandra KanaFaculty of Health Sciences, Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical TB Research, School of Pathology, University of the Witwatersrand and the National Health Laboratory Service, Johannesburg, South Africa.ORCID 0000-0001-9713-3480
University of the Witwatersrand · ZANational Health Laboratory Service · ZAImperial College London · GBIRCCS Ospedale San Raffaele · ITJohns Hopkins University · USKarolinska Institutet · SEKing's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the onset of COVID-19, the development of ex vivo laboratory models became an urgent priority to study host-pathogen interactions in response to the pandemic. In this study, we aimed to establish an ex vivo mucosal tissue explant challenge model for studying SARS-CoV-2 infection and replication. Nasal or oral tissue samples were collected from eligible participants and explants generated from the tissue were infected with various SARS-CoV-2 strains, including IC19 (lineage B.1.13), Beta (lineage B.1.351) and Delta (lineage B.1.617.2). A qRT-PCR assay used to measure viral replication in the tissue explants over a 15-day period, demonstrated no replication for any viral strains tested. Based on this, the ex vivo challenge protocol was modified by reducing the viral infection time and duration of sampling. Despite these changes, viral infectivity of the nasal and oral mucosa was not improved. Since 67% of the enrolled participants were already vaccinated against SARS-CoV-2, it is possible that neutralizing antibodies in explant tissue may have prevented the establishment of infection. However, we were unable to optimize plaque assays aimed at titrating the virus in supernatants from both infected and uninfected tissue, due to limited volume of culture supernatant available at the various collection time points. Currently, the reasons for the inability of these mucosal tissue samples to support replication of SARS-CoV-2 ex vivo remains unclear and requires further investigation.

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingHumansMucous MembraneAntibodies, Neutralizing

Identifiers

PMID37769001
PMCPMC10538748
OpenAlexW4387129746

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.